Chardan upgraded ProQR Therapeutics to Buy from Neutral with an unchanged price target of $2, which represents 48% upside. ProQR continues to advance its initial lead programs for its Axiomer platform ADAR-based therapeutics: AX-0810, the analyst tells investors in a research note. The firm cites valuation for the upgrade post the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRQR:
- ProQR Therapeutics reports Q3 EPS (EUR 0.07) vs (EUR 0.33) last year
- ProQR Announces Third Quarter 2023 Operating and Financial Results
- ProQR Therapeutics announces strengthened IP with new U.S. patent
- ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
- PRQR Earnings this Week: How Will it Perform?
